Intravitreal Bevacizumab for Age-Related Macular Degeneration

Phase 2

Terminated

• Conditions: Age Related Macular Degeneration

• Registration Number: NCT00347165
• Lead Sponsor: Asociación para Evitar la Ceguera en México

Brief Summary

The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration

Detailed Description

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined.

The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD

Study Timeline

• Study Start: 2005-09
• Primary Completion: 2006-06
• Study First Submitted: 2006-06-29
• Study First Submitted QC: 2006-06-30
• Study First Posted: 2006-07-04
• Study Completion: 2006-09
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-29
• Last Update Posted: 2024-05-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• age >50 age related macular degeneration

Exclusion Criteria

• moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Improvement of visual acuity at 6 months

Secondary Outcome Measures

Name	Time	Method
Leakiness in fluorangiography at 6 months
Retinal thickness at 6 months

Trial Locations

Locations (1)

Hospital Luis Sanchez Bulnes; 🇲🇽 MExico city, DF, Mexico